Surgeries & Interventions September 3, 2026
A Tale of Two Studies and the Importance of Patient Selection September 3, 2026
Two recent studies are forcing an important conversation in cardiology – some of the field's most common procedures may not be as clearly beneficial as open-label data originally suggests.
Cardiology Pharmaceuticals August 31, 2026
The Full Picture Clarifies Aficamten’s Impact on nHCM August 31, 2026
We are inching closer to a treatment for nonobstructive hypertrophic cardiomyopathy after Cytokinetics presented the full results from the ACACIA-HCM trial, showing that its cardiac myosin inhibitor, MYQORZO (aficamten), meaningfully improves how nHCM patients feel and function.
Cardiology August 27, 2026
Cardiology is Getting Older and Struggling to Keep Up August 27, 2026
Here’s an encouraging factoid –the number of cardiologists in the U.S. rose in the last 20 years. However, a recent JACC study suggests per-capita cardiologist density has actually declined since 2003, and the average cardiologist’s age keeps creeping higher.
Artificial Intelligence August 24, 2026
Context Matters for AI Diagnostic Performance August 24, 2026
With all the talk of AI outperforming and replacing doctors, a new JACC study reminds us – AI diagnostic algorithms don’t perform great when applied to populations different from the ones they’re trained on.
Heart Failure August 21, 2026
TARTAN-HF’s Targeted Tests for Diabetes Patients August 21, 2026
Scans to screen all 40M Americans with diabetes for HF would be nearly impossible, but the TARTAN-HF trial may have found a more streamlined method by leveraging the cardiometabolic connection.
Cardiac Imaging August 20, 2026
No Gadolinium Contrast? No Problem with VNE August 20, 2026
The gold standard for spotting myocardial scarring requires injecting gadolinium contrast during cardiac MRI, which adds time, cost, and a barrier for patients who can't receive it. Now a new study suggests AI may replace that injection in some cases.
Obesity Care August 17, 2026
Just How Bad is BMI at Predicting CVD Risk? August 17, 2026
We all know BMI is pretty useless for predicting CV risk, and a new JACC analysis puts hard numbers on just how much it misses, including a high-risk group hiding in plain sight among "normal weight" patients.
Surgeries & Interventions August 13, 2026
More Interventional Cardiologists, More Low-Value Stents August 13, 2026
The old adage that "built capacity gets used" applies to cardiology too. A Lown Institute study found that regions with the most PCI-performing physicians lead to a disproportionately higher share of patients receiving stents they’re unlikely to benefit from.
Cardiology Business August 10, 2026
iRhythm Expands MCT Footprint with VitalConnect Acquisition August 10, 2026
iRhythm, best known for its Zio cardiac monitoring wearables, is moving to expand well beyond its 14-day-patch roots by acquiring wearable biosensor company VitalConnect for $287.5M.
Cardiology Pharmaceuticals August 6, 2026
ZEUS Tells Us Inflammation Might Not Be the Answer August 6, 2026
Cardiovascular inflammation has been the talk of the town in cardiology, and while Novo Nordisk was wise to pursue treating it, results from the ZEUS trial have led to a thunderous debate on whether or not it ever played a role in ASCVD.
Cardiology August 3, 2026
How to Make Cardiologists Love Academia Again August 3, 2026
Cardiology is one of the most data-driven medical specialties a physician can pursue. So why is the source of that data – cardiac academia – declining in both workforce and prestige?
Cardiology Pharmaceuticals July 31, 2026
Another Look at Attruby Reveals Bolstered Benefits July 31, 2026
As the ATTR-CM market gets more crowded, medications will have to prove their place, and a sub-analysis of the ATTRibute-CM trial shows BridgeBio’s Attruby (acoramidis) has the efficacy to remain competitive.
Structural Heart July 30, 2026
Knowing When to Intervene in Mitral Regurgitation July 30, 2026
A common question in structural heart cardiology is “when do we know to intervene?” and recently released 25-year mitral regurgitation data might just have given us an answer.
Cardiology July 27, 2026
The Career Perceptions of Heart Failure Cardiology July 27, 2026
Picture this – you graduate medical school (not easy), you do a three-year internal medicine residency, then a three-year general cardiology fellowship, and another year of fellowship, but you’re paid less than your peers in other subspecialties – congrats, you’re an advanced heart failure cardiologist (AHFTC).
Cardiology Business July 23, 2026
The Cost of Cardiology is Driven by Insurers July 23, 2026
New price transparency data reveals how wildly insurance payments, reimbursements, and facility fees for cardiology swing across insurers and states, which underscores the complexity of U.S. healthcare costs.
Heart Failure July 22, 2026
How Earlier Hemodynamic Insight May Help Guide Heart Failure Management July 22, 2026
Heart failure continues to place a significant burden on patients and the healthcare system, with nearly 7 million Americans living with heart failure, with prevalence expected to reach nearly 9 million by 2030. Despite advances in guideline-directed medical therapy (GDMT), many patients still face high risks of hospitalization, mortality, and reduced quality of life.
Cardiology Pharmaceuticals July 20, 2026
An Oral PCSK9i and What it Means for Merck July 20, 2026
PCSK9 inhibitors are some of the most effective LDL-lowering drugs out there, but they’ve all required injection, and some even refrigeration. That just changed, however, with the FDA’s approval of Merck's Lipfendra (enlicitide), the first ever oral PCSK9i.
Cardiology Pharmaceuticals July 17, 2026
Can Kerendia Handle the (Blood) Pressure? More Findings from FINEARTS-HF. July 17, 2026
One year after its FDA approval for HF treatment, a new FINEARTS-HF substudy shows Bayer’s Kerendia (finerenone) isn’t just impervious to BP differences, it could actually give a small leg up to patients with hypertension.
Cardiac Imaging July 16, 2026
Zero CAC And The Cost of CCTA-QPA July 16, 2026
The power of a zero CAC score is facing fresh scrutiny after new plaque analysis data presented at SCCT 2026 shows just how much noncalcified plaque confers its own cardiovascular risk, despite the software’s financial barriers.